Erschienen in:
01.01.2012 | Editorial
The potential value of bursectomy in operations for trans-serosal gastric adenocarcinoma
verfasst von:
Scott A. Hundahl
Erschienen in:
Gastric Cancer
|
Ausgabe 1/2012
Einloggen, um Zugang zu erhalten
Excerpt
In the current issue, Fujita, Kurokawa, Sugimoto et al. describe interim results of an interesting two-armed non-inferiority trial that was designed to justify the potential elimination of bursectomy (also known as “omentobursectomy”) from a standard D2 operation for advanced gastric cancer. This is probably one of the last purely surgical trials to be reported for advanced disease, given the currently established role for adjuvant therapy [
1‐
3]. The trial was prematurely halted as a result of the convincing S-1 Trial [
3], which clearly demonstrated the value of adjuvant therapy in Asian patients following high-quality D2 resection. …